Competing interests
HT received honoraria from AstraZeneca plc, Bristol Myers Squibb, Chugai Pharma, Janssen, Kyowa Kirin, Meiji Seika Pharma, Nippon Shinyaku, Mundipharma, Ono Pharmaceutical, SymBio pharmaceuticals, Takeda Pharmaceutical, Eisai, Fujimoto and Sanofi. KO has received speaker honoraria from Janssen. The remaining authors declare no competing financial interests associated with this study.
Ethics approval and consent to participate
All methods were performed in accordance with the Declaration of Helsinki and relevant guidelines and regulations. This study was approved by the Institutional Review Board of the Japanese Red Cross Kyoto Daiichi Hospital (approval number: 1084). All participating patients provided written informed consent to the Japanese Society for Transplantation and Cellular Therapy at the time of registration.
